unknown
Stage
About
ErlySign develops a saliva-based, non-invasive diagnostic test for early detection of oral cancer that produces results in about 15 minutes. The company has secured funding and regulatory approvals and is scaling clinical trials and partnerships with oncology centers in India while advancing biomarker R&D for broader multi-cancer detection.
Explore ErlySign's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.